STAT

MARCH 17, 2025

Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. The agency also maintained Roche disseminated “erroneous information” about using biosimilars in combination therapy.

Biosimilars 224

Biosimilars Hospitals Pharmaceutical Companies Pharmaceutical Companies 224

Drug Patent Watch

DECEMBER 26, 2024

The FDA has also demonstrated that greater competition among generic drug makers can lead to lower generic drug prices. Studies have shown that the market entry of just a few generic competitors can yield generic prices below the brand price, and that generic drug prices decline with additional competition.

Drug Pricing 98

Drug Pricing Biosimilars 98

pharmaphorum

JANUARY 28, 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

Safe Biologics

FEBRUARY 1, 2024

The CHMP recognizes that there may be the potential to waive certain clinical data requirements even for complex biosimilars such as mAbs based on solid evidence of quality comparability.

Biosimilars 130

Biosimilars Documentation Drug Pricing 130

Safe Biologics

JANUARY 1, 2023

ASBM Adds Module on PBM Practices to OSU College of Pharmacy Biosimilars Course In December, ASBM recorded the seventh and final module in its biosimilar Continuing Education (CE) Course on Biosimilars, presented with the Ohio State University College of Pharmacy. Feldman explains unique features of the U.S. The bifurcated U.S.

Biosimilars 100

Biosimilars Drug Pricing 100

Pharmaceutical Technology

SEPTEMBER 15, 2022

YoY growth in revenue during the same period due to its robust pipeline, with Humira topping more than $20bn in sales in 2021, according to GlobalData’s Drugs Database. However, other challenges facing biopharmaceutical companies include growing generic drug competition, which places pressure on drug prices.

Vaccines 108

Vaccines Drug Pricing Biosimilars Documentation 108

pharmaphorum

FEBRUARY 18, 2021

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. “Patent losses could sink Allergan”.

Prescription Filling 52

Prescription Filling Drug Pricing Biosimilars Compounding 52